Trump's tariffs on generic drugs rattle India's pharma industry

Photo: Lech Pierchała · Pexels

The Trump administration has announced a plan to impose tariffs on generic drugs starting in 2028, with a two-year delay meant to give production time to shift toward the United States. Although the measure is still far off on the calendar, its mere confirmation already had an immediate market effect: several Indian pharmaceutical stocks, including Sun Pharmaceutical Industries, fell after the news broke.

India is one of the world's largest suppliers of generic medicines, including to the US market, so any change to the rules of access to that market carries considerable weight for the sector. The two-year window before tariffs take effect is meant precisely to test whether US industry can absorb a larger share of that production, a goal the administration has repeated across several economic fronts.

An experiment with an uncertain ending

Shifting generic drug manufacturing isn't simple: it requires specialized plants, regulatory approvals, and years of investment, none of which is solved by a tariff incentive alone. That's why this announcement also works as a test of how much trade policy can accelerate industrial processes that normally take much longer to mature.

Meanwhile, the stock reaction from Indian pharma companies reflects something common in these situations: markets tend to price in consequences long before a measure actually takes effect, even though the final outcome still depends on decisions yet to be made.